Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor webcast focused on preparing lonvo-z for patients with hereditary angioedema (HAE).
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor webcast focused on preparing lonvo-z for patients with hereditary angioedema (HAE)
- Presentation materials furnished as Exhibit 99.1, providing the detailed program update
- Event signals commercialization-readiness activity for Intellia’s lonvo-z HAE program
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted lonvo-z’s BLA with priority review and a March 10, 2027 PDUFA goal, advancing Intellia toward potential commercial launch
- Phase 3 HAELO met primary and key secondary endpoints, including 62% attack-rate reduction and 87% fewer attack-free weeks versus placebo
- Durability supports a one-time treatment model: 31 of 32 patients remained in long-term follow-up, with effects reported up to 4 years
- Lonvo-z 50 mg data covered 93 treated patients, with 55% reporting infusion-related reactions and two serious adverse events
- Commercial positioning targets chronic HAE treatment burdens, including lifetime medication use, insurance barriers and recurring administrationેણ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.